All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

PD-L1 methylation can predict survival in AML patients

By Cynthia Umukoro

Share:

Mar 10, 2017


In Acute Myeloid Leukemia (AML), the Programmed Death-1 (PD-1) pathway is hijacked by leukemic cells to facilitate immune evasion which can lead to poor outcomes in patients. AML cells upregulate their expression of Programmed Death Ligand 1 and 2 (PD-L1/PD-L2) thus leading to an inhibition of effector T-cell function via the PD-1 pathway. There is a paucity of data on the epigenetic regulation of PD-1/PD-L1 axis and the mechanism of promoter methylation of PD-L1 (CD274) and PD-L2 in AML has not been elucidated yet.

In a Letter to the Editor of Leukemia, Diane Goltz and colleagues from the University Hospital Bonn, Germany, investigated  whether there is any association between PD-L1/PD-L2 mRNA expression in AML and promoter methylation (mPD-L1/mPD-L2).

In this study, gene methylation and mRNA data were obtained from AML patient (n =197) diagnostic samples generated by the TCGA Research Network.

The key results of the study were:

  • Promoter methylation inversely correlated with the mRNA expression of PD-L1 (r = -0.458, P < 0.001) and PD-L2 (r = -0.408, P < 0.001)
  • Prolonged Overall Survival (OS [HR = 0.59, P = 0.003]), Event Free Survival (EFS [HR = 0.64 P = 0.011]) and reduced risk of relapse were associated with high mPD-L1 methylation

In summary, promoter methylation of PD-L1 can predict the survival outcomes of AML patients. The authors concluded by suggesting that PD-L1 methylation should be “considered as a companion biomarker” and should be analyzed in current clinical trials with PD-L1/PD-1 blockage in AML patients.

References

Your opinion matters

How important to you is the turnaround time for genetic testing in guiding your initial treatment decisions?